In vivo molecular imaging of angiogenesis in type 2 diabetes
- Conditions
- Type 2 diabetesMedDRA version: 20.0Level: LLTClassification code 10012613Term: Diabetes mellitus non-insulin-dependentSystem Organ Class: 100000004861Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05]
- Registration Number
- EUCTR2019-003466-41-DK
- Lead Sponsor
- Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine and PET
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- All
- Target Recruitment
- 90
•Written informed consent must be provided before participation
•Previous participation in the ”Kardiovaskulær risikoprofil hos personer med og uden type 2 diabetes vurderet med hjerte 82Rb-PET - Projekt-ID H-3-2013-015” study
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 45
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 45
•Pregnancy or breastfeeding (urine HCG is performed on all fertile women)
•Myocardial infarction = 30 days before inclusion
•Percutaneous coronary intervention = 4 weeks before inclusion
•Coronary artery bypass graft = 8 weeks before inclusion
•Heart transplantation
•Unstable angina
•Known severe heart failure (LVEF < 35 %)
•Known moderate-severe heart valve disease
•Known severe hypertrophy of left ventricle
•Uncontrolled arrhythmia, 2. or 3. degree AV-block or sick sinus syndrome - assessed from a standard 12-lead electrocardiogram
•Systolic blood pressure < 90 or > 200 mmHg
•Chronic obstructive pulmonary disease or asthma, defined as requirement of daily medical treatment
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method